PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...

In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%.

South Florida, an area with the highest rate of HIV/AIDS in the country, is already starting to feel the effects of the Trump ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing style you rely on, finding great stocks is made ...

Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.

In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.

The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing ...